A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

Condition:   Asthma
Intervention:   Biological: Mepolizumab
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified May 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.